Guideline Recommendations for Hypoglossal Nerve Stimulation (Inspire) in Obstructive Sleep Apnea

Patient Selection Criteria

The 2021 European Respiratory Society (ERS) guideline classifies hypoglossal nerve stimulation (HNS) as an established non‑CPAP therapy for moderate‑to‑severe obstructive sleep apnea (OSA) (AHI ≥ 15) and therefore recommends it for patients who meet these criteria, have a body‑mass index ≤ 35 kg/m², documented CPAP intolerance, and no contraindications. 1
The ERS guideline (2021) highlights that HNS was not recommended in the 2011 ERS statement because neuromuscular stimulation lacked sufficient evidence at that time. 2
Documentation of CPAP failure or intolerance is a mandatory prerequisite before proceeding with HNS, as stipulated by the ERS guideline. 1
Younger adult patients without excessive comorbidities are identified as having a favorable prognosis for HNS success according to the 2011 ERS guideline. 3

The ERS guideline (2021) states that HNS should be considered a primary alternative to CPAP for patients who cannot tolerate CPAP, rather than a salvage or last‑resort option. 1
In contrast, the 2011 ERS guideline classifies multilevel soft‑tissue surgery (e.g., uvulopalatopharyngoplasty) as a salvage therapy with unpredictable outcomes. [4][3]
The same 2011 ERS guideline indicates that traditional surgical approaches such as UPPP are only recommended for carefully selected patients and are associated with frequent long‑term side effects, making HNS a more predictable and effective option. [4][3]

Mandibular advancement devices are supported by the ERS (2011) as an effective treatment for mild‑to‑moderate OSA when HNS is unsuitable or declined. [2][5]
Maxillomandibular advancement is described in the 2011 ERS guideline as offering efficacy comparable to CPAP in younger patients with low BMI, although it is more invasive. 3

For patients who meet the standard inclusion criteria (moderate‑to‑severe OSA, BMI ≤ 35 kg/m², documented CPAP intolerance, and no contraindications), the ERS (2021) recommends offering HNS with the Inspire system as the preferred next‑line therapy after CPAP failure. 1

Patients with a body mass index ≥ 35 kg/m² (Class II/III obesity) should be referred to bariatric surgery as the primary therapeutic intervention rather than hypoglossal nerve stimulation, according to the American Academy of Sleep Medicine. 6